Awaiting development: Guidance and quality standards

Showing 261 to 270 of 303

Guidance and quality standards awaiting development
Title	Type
Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081	Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]	Technology appraisal guidance
Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]	Technology appraisal guidance
Technologies to support home monitoring of vision change in macular disease	Health technology evaluation
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [TSID11918]	Technology appraisal guidance
The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound	Medical technologies guidance
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]	Technology appraisal guidance
Tildrakizumab for treating active psoriatic arthritis [TSID12218]	Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]	Technology appraisal guidance
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]	Technology appraisal guidance